An invited commentary examining the ongoing debate around the clinical value of robotic platforms for cholecystectomy, weighing arguments from skeptics (cost, learning curve, bile duct injury risk, lack of evidence for fewer open conversions) against proponents (precision, complex case capability, ergonomics, lower conversion rates).
This is an invited commentary with no original data, patient cohort, or quantitative analysis — conclusions are opinion-based and not drawn from a primary study.
The value of robotic cholecystectomy remains unresolved; clinicians should critically weigh institutional, ergonomic, and patient-centered factors rather than adopt the platform based on marketing or branding alone.
Explore related topics
